Posted by Michael Wonder on 06 Mar 2024
Trellis Bioscience's TRL1068 receives FDA fast track and QIDP designations, amplifying commitment to combat infectious diseases
6 March 2024 - Trellis Bioscience is thrilled to announce that its lead antibody candidate, TRL1068, has been granted fast track and QIDP designations by the US FDA.
These designations play a pivotal role in advancing Trellis Bioscience's pipeline, particularly in the development of novel therapies for prosthetic joint infections and other challenging bacterial infections.
